EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The “Road” to Malignant Transformation from Endometriosis to Endometriosis-Associated Ovarian Cancers (EAOCs): An mTOR-Centred Review

Radwa Hablase, Ioannis Kyrou iD, Harpal Randeva, Emmanouil Karteris, Jayanta Chatterjee iD

Cancers · 06.06.2024 · 16 (11) · 2160

DOI: 10.3390/cancers16112160 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 06.06.2024. Verfasst von Radwa Hablase und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Health, Medicine and Life Sciences, Brunel University London, Uxbridge UB83PH, UK. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 200 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer is an umbrella term covering a number of distinct subtypes. Endometrioid and clear-cell ovarian carcinoma are endometriosis-associated ovarian cancers (EAOCs) frequently arising from ectopic endometrium in the ovary. The mechanistic target of rapamycin (mTOR) is a crucial regulator of cellular homeostasis and is dysregulated in both endometriosis and endometriosis-associated ovarian cancer, potentially favouring carcinogenesis across a spectrum from benign disease with cancer-like characteristics, through an atypical phase, to frank malignancy. In this review, we focus on mTOR dysregulation in endometriosis and EAOCs, investigating cancer driver gene mutations and their potential interaction with the mTOR pathway. Additionally, we explore the complex pathogenesis of transformation, considering environmental, hormonal, and epigenetic factors. We then discuss postmenopausal endometriosis pathogenesis and propensity for malignant transformation. Finally, we summarize the current advancements in mTOR-targeted therapeutics for endometriosis and EAOCs.

Schlagwörter

Stichwörter der Autor:innen

clear-cell carcinomaendometrioid ovarian carcinomaendometriosismTORmTOR inhibitorsovarian cancer

Autor:innen und Institutionen

  • College of Health, Medicine and Life Sciences, Brunel University London, Uxbridge UB83PH, UK.
  • Academic Department of Gynaecological Oncology, Royal Surrey NHS Foundation Trust Hospital, Guildford GU2 7XX, UK.
  • Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust, Coventry CV2 2DX, UK.
  • Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK.
  • Institute for Cardiometabolic Medicine, University Hospitals Coventry and Warwickshire NHS Trust, Coventry CV2 2DX, UK.
  • Centre for Sport, Exercise and Life Sciences, Research Institute for Health & Wellbeing, Coventry University, Coventry CV1 5FB, UK.

ORCID-Profile: Ioannis Kyrou, Jayanta Chatterjee

Zitieren

APA

Hablase, R., Kyrou, I., Randeva, H., Karteris, E., & Chatterjee, J. (2024). The “Road” to Malignant Transformation from Endometriosis to Endometriosis-Associated Ovarian Cancers (EAOCs): An mTOR-Centred Review. Cancers, 16(11), 2160. https://doi.org/10.3390/cancers16112160

Vancouver

Hablase R, Kyrou I, Randeva H, Karteris E, Chatterjee J. The “Road” to Malignant Transformation from Endometriosis to Endometriosis-Associated Ovarian Cancers (EAOCs): An mTOR-Centred Review. Cancers. 2024;16(11):2160. doi:10.3390/cancers16112160

BibTeX
@article{Hablase2024,
  author = {Hablase, Radwa and Kyrou, Ioannis and Randeva, Harpal and Karteris, Emmanouil and Chatterjee, Jayanta},
  title = {The “Road” to Malignant Transformation from Endometriosis to Endometriosis-Associated Ovarian Cancers (EAOCs): An mTOR-Centred Review},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {11},
  pages = {2160},
  doi = {10.3390/cancers16112160}
}
Kostenlos starten →